First of all, I don't want to suggest that we haven't had commercial success. Allen Eaves leads a company called STEMCELL Technologies that 20 years ago came out of research in his lab at the BC Cancer Agency. Over the last 20 years it has been growing to the point where it's approaching $200 million in revenue. It employs 800 people and exports its product, and 95% of its sales come from outside of Canada. So we do have some successes. The point we're making is that we're really at a threshold, and other jurisdictions have realized that, where oftentimes the science was a lot of hope, but in the last decade we've seen more and more therapies move into clinical trials. We've seen countries and jurisdictions rally around trying to attract more clinical trials to their jurisdictions.
I think one of the biggest barriers we've had in Canada has been that we have started almost always with academic research first. We've developed a really strong capability. By any academic measure, Canada is one of the top two or three countries in the world. What we're asking in our initiative is that we need to re-engage the private sector, whether it be private equity, or the industrial sector, or working with the health charities, to support the translation of that into clinical trials. In Canada, we have very few institutional industry-led clinical trials that are happening in this area and there's a lot more that we can do there. So part of our request, and a big portion of our request, is to be supporting some of those early-stage clinical trials.